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The plasma pharmacokinetics of danofloxacin was studied in healthy Afri-
can catfish (Clarias gariepinus) following a single intravenous (IV) and intramus-
cular (IM) administration of 10 mg/kg at 22 °C. Catfish were divided into two 
groups (each group containing 78 fish), then danofloxacin mesylate (10 mg/kg) 
was administered IV (into the caudal vein) in Group 1 and IM (into the right 
epaxial muscle) in Group 2, and blood was obtained from the caudal vein before 
(0 h) and after (0.25, 0.5, 1, 2, 4, 8, 12, 24, 36, 48, 72 and 96 h) of drug admin-
istration. High-performance liquid chromatography was used for the determina-
tion of plasma concentration, and a non-compartmental model was used for the 
analysis of pharmacokinetic parameters. After IV administration, elimination half-
life (t1/2ʎz, 24.49 h), mean residence time (MRT, 30.14 h), volume of distribution 
at steady state (Vdss, 1.07 L/kg) and total body clearance (CLT, 0.035 L/h/kg) 
were determined. After IM administration, t1/2ʎz, MRT, peak concentration (Cmax), 
time to reach Cmax and bioavailability were 47.64 h, 61.06 h, 5.22 μg/mL, 1 h and 
67.12%, respectively. After IM administration, danofloxacin showed good bio-
availability and long t1/2ʎz. The favourable pharmacokinetic characteristics after 
IM administration support the use of danofloxacin for the treatment of susceptible 
bacterial infections in catfish.  
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The raising of large numbers of fish in aquaculture has increased the risk 
of occurrence of bacterial diseases (Cabello, 2006; Canada-Canada et al., 2009; 
Miranda et al., 2018). 
The African catfish (Clarias gariepinus) is one of the most important 
freshwater fishes and a fish commonly raised in aquaculture (Authman et al., 
2013). Catfish has a high resistance to a wide range of pollutions, poor water 
quality, and oxygen depletion. It has commercial importance, being considered 
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one of the best alternatives to tilapia, and it is excellent for aquaculture as it is 
omnivorous and grows fast (Rad et al., 2004; Adewolu et al., 2008). 
Antibiotics used to treat bacterial diseases in fish were not developed for 
these species, and dosages from other species were used for fish (Smith, 2008). 
Unsuccessful treatment, toxicity, drug residues and bacterial resistance develop-
ment due to inaccurate dosage regimen are threats to public health (Capkin et al., 
2015). Therefore, pharmacokinetic and pharmacodynamic parameters were used 
to estimate the efficacy of antimicrobial drugs and determine the suitable dosage 
regimen (Theuretzbacher, 2012). 
In aquaculture, fluoroquinolones have been used to treat bacterial infec-
tions in fish (Brown, 1996). These compounds have broad-spectrum effects and 
are generally used for the treatment of skin, digestive, respiratory and urinary 
tract infections and septicaemia (Fadel et al., 2018). At low concentrations, they 
are effective against fish pathogens and provide excellent systemic distribution 
(Samuelsen, 2006; Samanidou and Evaggelopoulou, 2007). 
Danofloxacin inhibits the bacterial DNA gyrase enzyme and has bacteri-
cidal activity (Dimitrova et al., 2014; Tian et al., 2019). It has antimicrobial ac-
tivity against numerous Gram-negative and some Gram-positive bacteria and is 
recommended for the treatment of skin infections and septicaemia in fish (Fan et 
al., 2015; Corum et al., 2018). High bioavailability, long elimination half-life, 
good penetration into phagocytic cells, excellent tissue penetration and low 
plasma protein binding were specific features for danofloxacin (Giguere et al., 
1996; Karademir et al., 2015). 
The kinetics of danofloxacin was investigated in fish like tilapia (Fan et al., 
2015) and brown trout (Corum et al., 2018). As there are hardly any data on the 
pharmacokinetics of danofloxacin in catfish, this study investigated the pharmaco-
kinetics of danofloxacin in catfish after single intravenous (IV) and intramuscular 
(IM) administrations at a dose of 10 mg/kg. The pharmacokinetic (PK) and phar-
macodynamic (PD) parameters using PD data reported for susceptible pathogens 
were also determined. 
 
Materials and methods 
Chemicals 
Danofloxacin (of analytical grade) was obtained from Sigma-Aldrich (St. 
Louis, MO, USA). Acetonitrile, triethylamine and orthophosphoric acid were ob-
tained from Merck (Darmstadt, Germany) and Advocin® 2.5%, 25 mg/mL inject-
able solution from Pfizer Animal Health Division (Cairo, Egypt). 
Experimental fish 
Male African catfish (C. gariepinus) were obtained from the River Nile at 
Benha (body weight: 450 ± 28 g) and acclimatised for two weeks in 220-litre 
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glass tanks (100 cm × 40 cm × 55 cm) containing tap water (temperature: 22.3 ± 
0.2 °C; pH: 7.5 ± 0.18; dissolved oxygen: 6.5 ± 0.70 mg/L) and were fed on a 
commercial pellet diet (Skriting Egypt Company) and kept at a photoperiod of 
12:12 light : dark). At three-day intervals, water in the tanks was siphoned off 
completely together with fish faeces and replaced with aerated tap water from a 
water storage tank. The study was approved by the Ethics Committee of the Fac-
ulty of Veterinary Medicine, Benha University, Egypt. 
Experimental design 
The catfish were divided into two groups (each group containing 78 fish), 
then danofloxacin mesylate (10 mg/kg) was administered IV (into the caudal vein) 
in Group 1 and IM (into the right epaxial muscle) in Group 2. Six fish were used 
at each sampling time. One mL blood was obtained under anaesthesia (tricaine 
methanesulphonate, 200 mg/L) from the caudal vein, before (0 h) and after (0.25, 
0.5, 1, 2, 4, 8, 12, 24, 36, 48, 72 and 96 h) drug administration. Then the samples 
were collected into heparin-containing anticoagulant tubes, centrifuged for 10 min 
at 4000 g, and plasma samples were obtained and stored at –20 °C until analysis. 
Analytical procedure 
The plasma concentrations of danofloxacin were measured using high-
performance liquid chromatography (HPLC) (Shimadzu, Tokyo, Japan) (Corum et 
al., 2018). Acetonitrile (200 μL) was added to plasma (100 μL), vortexed (1 min), 
the mixture was centrifuged at 10,000 g for 10 min, the supernatant was transferred 
to HPLC vials, and 10 μL supernatant was injected into the HPLC. For chroma-
tographic separation, a GeminiTM C18 column (250 × 4.6 mm; internal diameter: 
5 μm; Phenomenex, Torrance, CA, USA) was used. The autosampler was at room 
temperature and the column temperature was maintained at 40 °C. The mobile 
phase [acetonitrile and 0.4% orthophosphoric acid, including 0.4% triethylamine 
(18:82 v/v)], was pumped into HPLC using a low-pressure gradient system at a 
flow rate of 1 mL/min. Ultraviolet-visible detection (SPD-10A) was set at 280 nm 
wavelength.  
The calibration standards prepared for the plasma (0–100 μg/mL) were 
linear. The limits of quantitation and detection for the plasma were 0.04 μg/mL. 
Quality control samples prepared for the plasma at 0.2, 2 and 20 μg/mL were 
used to determine recovery, which was 95.96, 95.03 and 94.18%, respectively, 
and the intra- and inter-day coefficients of variation were < 5.13%. 
Pharmacokinetic calculations 
Pharmacokinetic calculations were made using WinNonlin 6.1 (Pharsight 
Corporation, Scientific Consulting Inc., NC, USA). The PK parameters were as-
sessed by non-compartmental model analysis. After IV administration, AUC, t1/2ʎz, 
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MRT (AUMC/AUC), CLT (Dose/AUC) and Vdss (Cl.MRT) in the plasma were 
determined, while for IM administration AUC, t1/2ʎz, MRT and F = AUC0–∞IM/ 
AUC0–∞IV × 100 were calculated. Peak concentrations (Cmax) and (Tmax) of da-
nofloxacin were determined via direct inspection of the plasma concentration–
time curve. 
Pharmacodynamic calculations 
The efficacy of danofloxacin depends on the AUC0–24/MIC and Cmax/MIC 
ratios. The MIC of danofloxacin against bacteria isolated from catfish has not 
been determined yet. The MIC values of danofloxacin against bacteria isolated 




The plasma concentration–time curve and PK parameters after IV and IM 
administrations of danofloxacin at a single dose of 10 mg/kg in catfish are shown 
in Fig. 1 and Table 1, respectively. Danofloxacin showed lower AUC and longer 
plasma t1/2ʎz and MRT0–∞ after IM administration than after IV administration. Af-
ter IV administration, Vdss and ClT were 1.07 L/kg and 0.035 L/h/kg, respectively. 
After IM administration, Tmax and Cmax were 1 h and 5.22 μg/mL, respec-
tively. The bioavailability was 67.12% after IM administration. Regarding the 
pharmacodynamics of danofloxacin, the AUC0–24/MIC and Cmax/MIC ratios for 
pathogens with 0.5 μg/mL MIC were 140.38 and 10.45, respectively, after IM 
administration of danofloxacin at a dose of 10 mg/kg, while the AUC0–24/MIC 
and Cmax/MIC ratios for susceptible pathogens with 0.5 μg/mL MIC were < 125 
and < 10, respectively.  
 
Discussion 
After administrations of danofloxacin in catfish either by the IV or the IM 
route, no local or systemic side effects were detected. Similarly, following da-
nofloxacin administration to tilapia and sea bass, no adverse effects were ob-
served (Fan et al., 2015; Vardali et al., 2017). 
Following IV administration of danofloxacin in catfish the t1/2ʎz was 24.49 h. 
This figure was consistent with the data reported for flumequine (24.6 h) in cat-
fish (Plakas et al., 2000), sarafloxacin (22.6 h) in silver crucian carp (Fang et al., 
2016b), was higher than that of enrofloxacin (17.44 h) in Korean catfish (Kim et 
al., 2006) and enrofloxacin (19.82 h) in snakehead fish (Fang et al., 2016a), and 
lower than that of enrofloxacin (63.5 h) in silver crucian carp (Fang et al., 2012).  
After IV administration, danofloxacin showed good penetration and tissue 
distribution in catfish, as the Vdss was 1.07 L/kg. This value was higher than that 
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recorded for flumequine (0.52 L kg–1) in catfish (Plakas et al., 2000) and for en-
rofloxacin (0.38 L kg–1) in European cuttlefish (Gore et al., 2005), and lower 
than that determined for enrofloxacin (3.93, 3.40 L kg–1) in Korean catfish and 
brown trout, respectively (Kim et al., 2006; Koc et al., 2009). 
 
Fig. 1. Semi-logarithmic graph depicting the time–concentration of danofloxacin in the plasma of 
catfish after a single IV (○) and IM (■) administration of 10 mg/kg body weight (n = 6) 
Table 1 
Plasma pharmacokinetic parameters of danofloxacin in catfish following IV and IM administration 
of 10 mg/kg body weight (mean ± SE; n = 6) 
Parameters Unit IV IM 
t1/2ʎz h 24.49 ± 0.59 47.64 ± 3.66 
AUC0–24 μg mL
–1 h–1 157.93 ± 9.71 70.19 ± 3.41 
AUC0–96 μg mL
–1 h–1 270.88 ± 19.21 148.15 ± 8.16 
AUC0–∞ μg mL
–1 h–1 287.18 ± 21.12 189.16 ± 11.55 
AUMC μg mL–1 h–2 8708.3 ± 815.9 11633.9 ± 1029 
MRT h 30.14 ± 0.63 61.06 ± 3.42 
Vdss L kg
–1 1.07 ± 0.06 – 
ClT L kg
–1 h–1 0.035 ± 0.002 – 
Cmax μg mL
–1 – 5.22 ± 0.12 
tmax h – 1.00 ± 0.00 
F % – 67.12 ± 5.45 
AUC0–24/MIC Ratio – 140.38 ± 6.83 
Cmax/MIC Ratio – 10.45 ± 0.25 
t1/2ʎz: elimination half-life; AUC: area under plasma concentration–time curve; AUMC: area under 
moment curve; MRT: mean residence time; Vdss: volume of distribution at steady state; ClT: total 
body clearance; Cmax: maximum plasma concentration; tmax: time to peak plasma concentration; F: 
bioavailability; MIC: minimum inhibitory concentration 
 
The total body clearance (CLT) was 0.035 L/kg/h; this value was close to 
that reported for enrofloxacin (0.04 L/kg/h) in crucian carp (Fang et al., 2012), 
lower than that found for flumequine (0.14 L/kg/h) in catfish (Plakas et al., 2000) 
Time (h) 
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and for enrofloxacin (0.14 L/kg/h) in brown trout (Koc et al., 2009), for en-
rofloxacin in cuttlefish (0.28 L/kg/h; Gore et al., 2005), Korean catfish and 
brown trout (0.137 L/kg/h; Kim et al., 2006) and snakehead fish (0.13 L/kg/h; 
Fang et al., 2016a), as well as for sarafloxacin (0.18 L/kg/h) in silver crucian 
carp (Fang et al., 2016b). 
Pharmacokinetic parameters were affected by size and environment (pH, 
temperature and ion content), species differences, variation in dose, route of ad-
ministration, age, and body condition (Intorre et al., 2000). In contrast to mam-
mals, fish can adapt to low temperatures and adjust their biochemical and phys-
iological functions based on their ambient temperature as they are heterothermic 
animals; thus, tissue perfusion and cardiac output depend on the ambient temper-
ature in fish (Lees and Aliabadi, 2002). 
Following IM administration, the elimination half-life (t1/2ʎz) of danofloxa-
cin was 47.64 h, which is longer than that found for danofloxacin in brown trout 
(28.28 h; Corum et al., 2018) and shorter than that reported for enrofloxacin in 
crucian carp (80.95 h; Shan et al., 2018). Maximal plasma concentration (Cmax) 
was 5.22 μg/ml, achieved at a tmax of 1 h. These values were similar to that of da-
nofloxacin (4.79 μg/ml) achieved at 1 h in brown trout (Corum et al., 2018). 
The bioavailability of danofloxacin in catfish was 67.12%. This value in-
dicated a moderate absorption of danofloxacin from catfish muscles. It was con-
sistent with that previously reported for danofloxacin in brown trout (55.99%; 
Corum et al., 2018). Fluoroquinolones are non-ionised and amphoteric (pKa: 6.2 
and 9.4) at pH 6–8 (Brown, 1996). So the penetration of danofloxacin into fish 
muscle could be considered sufficient at a pH of 7 (Gatica et al., 2010). Freshwa-
ter fish use the skin and the gills for osmoregulation; thus, following IM admin-
istration, drugs can also be eliminated via the skin. In fish, intramuscularly ad-
ministered drugs have also been recorded to seep through the injection channel 
(Wilkie et al., 2006). Also, the bioavailability of drugs in fish was shown to be 
affected by water temperature (Corum et al., 2018). These differences in bioa-
vailability may be related to water chemistry (pH, ion content), which are re-
garded as important factors in the stability of drugs. Also, chelation with cations 
occurred as a result of ionisation at higher pH, and the bioavailability of quin-
olones was reported to be lower in seawater than in freshwater (Intorre et al., 
2000; Kim et al., 2006). 
The efficacy of antibacterial drugs based on concentration is calculated by 
the Cmax/MIC and AUC/MIC ratios. For the prevention of antibacterial resistance 
and for effective treatment, AUC/MIC > 125 and Cmax/MIC > 10 were recom-
mended (Miravitlles, 2005; Theuretzbacher, 2012). The MIC value of danofloxa-
cin for bacteria isolated from catfish has not been estimated, but those of da-
nofloxacin against pathogens with 0.5 μg/mL MIC were 140.38 and 10.45, re-
spectively (Lu, 2006). The AUC0–24/MIC and Cmax/MIC ratios for susceptible 
pathogens were < 125 and < 10, respectively.  
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In conclusion, IM administration of danofloxacin in catfish exhibited 
longer t1/2ʎz and moderate bioavailability. After IM administration of danofloxa-
cin (10 mg/kg) in catfish, the values of AUC0–24/MIC > 125 and Cmax/MIC > 10 
would be expected to successfully treat catfish infected by strains with MIC val-
ues ≤ 0.5 μg/mL. Further studies are needed to determine the in vitro and in vivo 
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